Kalaris Therapeutics, Inc. (KLRS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has a cash flow conversion efficiency ratio of -0.195x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.35 Million) by net assets ($68.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Kalaris Therapeutics, Inc. to measure how many days the company can operate on defensive assets alone.
Kalaris Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kalaris Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tait Marketing & Distribution Co Ltd
TWO:5902
|
0.062x |
|
CVC Income & Growth Limited
LSE:CVCE
|
0.023x |
|
Orian Sh.M. Ltd
TA:ORIN
|
0.107x |
|
SinoMedia Holding Limited
F:SJY
|
0.012x |
|
Climb Global Solutions
NASDAQ:CLMB
|
-0.102x |
|
Wellspire Holdings Berhad
KLSE:0271
|
-0.129x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
0.008x |
|
Pollux Investasi Internasional Tbk PT
JK:POLI
|
0.013x |
Annual Cash Flow Conversion Efficiency for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Kalaris Therapeutics, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Kalaris Therapeutics, Inc. (KLRS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.81 Million | $-42.98 Million | -0.545x | +8.74% |
| 2024-12-31 | $113.31 Million | $-67.70 Million | -0.598x | -290.34% |
| 2023-12-31 | $-45.02 Million | $-14.13 Million | 0.314x | -2.82% |
| 2022-12-31 | $-30.27 Million | $-9.78 Million | 0.323x | +168.44% |
| 2021-12-31 | $225.27 Million | $-106.32 Million | -0.472x | -174.02% |
| 2020-12-31 | $353.06 Million | $-60.81 Million | -0.172x | -3.94% |
| 2019-12-31 | $121.62 Million | $-20.16 Million | -0.166x | -284.07% |
| 2018-12-31 | $21.58 Million | $1.94 Million | 0.090x | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more